Can a jolt to the immune system slow Alzheimer's? new study begins
NCT ID NCT05606341
First seen Jan 11, 2026 · Last updated May 01, 2026 · Updated 17 times
Summary
This early-stage study tests whether a drug called CpG 1018, which stimulates the body's natural immune system, is safe for people with mild cognitive impairment or mild Alzheimer's dementia. About 39 participants will receive one of three doses or a placebo over 8 weeks. The main goal is to check for side effects and immune reactions, not yet to measure if it helps memory.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MILD COGNITIVE IMPAIRMENT are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
NYU Langone Health
RECRUITINGNew York, New York, 10016, United States
Conditions
Explore the condition pages connected to this study.